Amy Pai1, Kamron Khan2, Kaoru Fujinami2, Michel Michaelides2,3
Purpose: To present a case series of molecularly conﬁrmed ABCA4 retinopathy patients with choroi- dal neovascular membranes (CNVM) from Moor- ﬁeld’s Eye Hospital.
Methods: A retrospective data search was con- ducted using our electronic medical records. CNVM was diagnosed based on clinical examinations and retinal imaging modalities including fundus ﬂuores- cein angiography (FFA) and optical coherence tomography (OCT)-Angiography.
Results: We found 618 patients with molecularly conﬁrmed ABCA4 mutations from 2000 to 2017, of whom 4 had CNVM during the follow up period. They were offered Anti-vascular endothelial growth factor (Anti-VEGF) injections. Five eyes of 4 patients were included. At the time of presentation, the ages were 8, 39, 57, and 57 years. Starting visual acuities (VA) in the CNVM affected eyes were 6/9, 6/18, 6/36, 6/36, 6/76 (mean 6/21) and their respective VA at the last consultation were 6/6, 6/24, 6/24, 6/36, 6/76 (mean 6/18). The mean follow up period was 41 months and the number of injections received per eye ranged from 4 to 19. One patient was not treated with Anti-VEGF injections due to the location and spontaneous regression of the CNVM.
Conclusions: In our cohort, we found the incidence of CNVM in patients with ABCA4 retinopathy was low (0.65%). We present OCT, FFA, and OCT- Angiography ﬁndings in our patients. Anti-VEGF injections helped these patients with an inherited ret- inal dystrophy and CNVM, and a few patients were able to maintain pre treatment VA. This is one of the few case series of CNVM in patients with molecularly conﬁrmed ABCA4 associated retinopathy.
IRREVERSIBLE LENALIDOMIDE RELATED OPTIC NEUROPATHY IN A PATIENT WITH CHRONIC MYELOID LEUKAEMIA
A cost-effectiveness analysis of AcrySof IQ vivity intraocular lens from private health fund perspective in Australia
Efficacy and safety of intravitreal pegcetacoplan in geographic atrophy: Results from the phase 3 DERBY and OAKS trials